Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
David M. Simpson,A. Blitzer,Allison Brashear,Cynthia L. Comella,Richard Dubinsky,Mark Hallett,Joseph Jankovic,Barbara I. Karp,Christy L. Ludlow,J. M. Miyasaki,M. Naumann,Yuen T. So +11 more
TLDR
An evidence-based review of the safety and efficacy of botulinum neurotoxin in the treatment of adult and childhood spasticity found the highest quality literature available for the respective indications was as follows.Abstract:
Objective: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of movement disorders. Methods: A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and selected movement disorders. Authors reviewed, abstracted, and classified articles based on American Academy of Neurology criteria (Class I–IV). Results: The highest quality literature available for the respective indications was as follows: blepharospasm (two Class II studies); hemifacial spasm (one Class II and one Class III study); cervical dystonia (seven Class I studies); focal upper extremity dystonia (one Class I and three Class II studies); focal lower extremity dystonia (one Class II study); laryngeal dystonia (one Class I study); motor tics (one Class II study); and upper extremity essential tremor (two Class II studies). Recommendations: Botulinum neurotoxin should be offered as a treatment option for the treatment of cervical dystonia (Level A), may be offered for blepharospasm, focal upper extremity dystonia, adductor laryngeal dystonia, and upper extremity essential tremor (Level B), and may be considered for hemifacial spasm, focal lower limb dystonia, and motor tics (Level C). While clinicians’ practice may suggest stronger recommendations in some of these indications, evidencebased conclusions are limited by the availability of data. Neurology ® 2008;70:1699–1706read more
Citations
More filters
Journal ArticleDOI
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.
TL;DR: The pharmacological properties and mode of action of BoNTs have shed light on general principles of neuronal transport and protein-protein interactions and are stimulating basic science studies, and suggest novel uses in therapeutics with increasing disease/symptom specifity.
Journal ArticleDOI
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology
David M. Simpson,Mark Hallett,Eric J. Ashman,Cynthia L. Comella,Mark W. Green,Gary S. Gronseth,Melissa J. Armstrong,David Gloss,Sonja Potrebic,Joseph Jankovic,Barbara P. Karp,Markus Naumann,Yuen T. So,Stuart A. Yablon +13 more
TL;DR: The 2008 AAN guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia, headache, and adult spasticity are updated and onaBoNT-A is established as ineffective and should not be offered for episodic migraine and is probably ineffective for chronic tension-type headaches.
Journal ArticleDOI
Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Markus Naumann,Yuen T. So,C. E. Argoff,Martin K. Childers,Dennis D. Dykstra,Gary S. Gronseth,Bahman Jabbari,Horacio Kaufmann,Brigitte Schurch,Stephen D. Silberstein,David M. Simpson +10 more
TL;DR: An evidence-based review of the safety and efficacy of botulinum neurotoxin in the treatment of movement disorders found that clinicians’ practice may suggest stronger recommendations in some of these indications, but evidencebased conclusions are limited by the availability of data.
Journal ArticleDOI
EFNS guidelines on diagnosis and treatment of primary dystonias
Alberto Albanese,Friederich Asmus,Kailash P. Bhatia,Antonio E. Elia,Bulent Elibol,Graziella Filippini,Thomas Gasser,Joachim K. Krauss,Nardo Nardocci,Alistair Newton,Josep Valls-Solé +10 more
TL;DR: This document is intended to provide a revised version of earlier guidelines published in 2006, and is likely to be modified in the future to reflect the changing needs of the rapidly changing environment.
Journal ArticleDOI
Treatment of patients with essential tremor
TL;DR: A newly developed algorithm, based on the logarithmic relation between tremor amplitude and clinical tremor ratings, can be used to compare the magnitude of effect of available treatments.
References
More filters
Journal ArticleDOI
Identification of the Major Steps in Botulinum Toxin Action
TL;DR: This review seeks to identify and characterize all major steps in toxin action, from initial absorption to eventual paralysis of cholinergic transmission, as well as an agent that can be used to treat disease.
Journal ArticleDOI
Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.
Allison Brashear,Mark Forrest Gordon,Elie P. Elovic,V. Daniel Kassicieh,Christina Marciniak,Mai Do,Chia Ho Lee,Stephen Jenkins,Catherine C. Turkel +8 more
TL;DR: Intramuscular injections of botulinum toxin A reduce spasticity of the wrist and finger muscles and associated disability in patients who have had a stroke.
Journal ArticleDOI
How botulinum and tetanus neurotoxins block neurotransmitter release.
TL;DR: How the proteolytic attack at specific sites of the targets for BoNTs and TeNT induces perturbations of the fusogenic SNARE complex dynamics and how these alterations can account for the inhibition of spontaneous and evoked quantal neurotransmitter release by the neurotoxins are explained.
Journal ArticleDOI
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Allison Brashear,Mark F. Lew,Dennis D. Dykstra,Cynthia L. Comella,Stewart A. Factor,Robert L. Rodnitzky,Richard Trosch,Carlos Singer,Mitchell F. Brin,J. J. Murray,J. D. Wallace,A. J. Willmer-Hulme,M. Koller +12 more
TL;DR: Improvements associated with BoNT/B treatment were greatest for patients who received the 10,000-U dose, and Botulinum toxin type B (NeuroBloc) is safe and efficacious at 5,000 U and 10, thousand U for the management of patients with cervical dystonia.
Journal ArticleDOI
Botulinum toxin type A in the treatment of upper extremity spasticity : A randomized, double-blind, placebo-controlled trial
David M. Simpson,D. N. Alexander,C. F. O'Brien,Michele Tagliati,A. S. Aswad,J. M. Leon,J. Gibson,J. M. Mordaunt,E. P. Monaghan +8 more
TL;DR: BTXA safely reduced upper extremity muscle tone in patients with chronic spasticity after stroke and reported significant improvement on the physician and patient Global Assessment of Response to Treatment at weeks 4 and 6 postinjection.